...in 2018, NBC News reported that FluMist was pulled off the U.S. market in 2016 “because it barely worked against one common strain of flu in kids.” The FDA did not mention the 2016 withdrawal in its Sept. 20 statement approving the vaccine for self- or caregiver administration.

In 2018, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices “voted 12-2 to add FluMist back to the mix of flu vaccines that doctors and clinics can use,” NBC News reported at the time.

Two panel members said they were worried about “hurting children and further undermining the public’s perception of the safety of flu vaccines if FluMist comes back on the market and does not work well,” NBC News added.

According to VAERS data, a total of 11,065 adverse events have been reported in connection with FluMist products — including 943 that were classified as “serious.” About half of the reports were for children under 17 years old.

VAERS data show 48 reports of adverse events resulted in death — including 23 deaths in children under 17, with an additional 13 deaths listed with an “unknown” age....

“AstraZeneca has a horrible track record, considering that its COVID-19 vaccine offering (based on a chimpanzee adenovirus) led to so many serious adverse events that it was taken off the market voluntarily by the manufacturer,” Hooker said.

“We would be remiss if we didn’t discuss the merger of AstraZeneca with Novartis to create a new company, Syngenta,” Perro said. “They were the company that harassed UC Berkeley professor, Dr. Tyrone Hayes, who exposed the endocrine-disrupting toxic effects of their pesticide, atrazine,” Perro said.

“Is this the company we should trust to create a ‘take-out’ vaccine to administer at home?” Perro asked.

AstraZeneca is facing a class-action lawsuit in the U.K. filed by people injured by the company’s COVID-19 vaccine and by claimants acting on behalf of a loved one who allegedly died from vaccine-induced blood-clotting issues....